Results 191 to 200 of about 301,296 (304)
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest +3 more
wiley +1 more source
Elastic stockings for venous thromboembolism prevention, time to go. [PDF]
Roberts LN, Gee E.
europepmc +1 more source
Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), and is an important and growing public health issue. DVT is a blood clot that forms in the deep veins of the body and PE occurs when a clot breaks free and
core
Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou +5 more
wiley +1 more source
Multi-Omics Prioritization and Clinical Evaluation of CYP4V2 as a Candidate Biomarker in Venous Thromboembolism. [PDF]
Zhang C +9 more
europepmc +1 more source
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann +3 more
wiley +1 more source
Trends in Direct Oral Anticoagulant Use for Cancer-Associated Venous Thromboembolism.
Varnier R +6 more
europepmc +1 more source
Management of Recurrent Venous Thromboembolism on Anticoagulation. [PDF]
Eatrides J +6 more
europepmc +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source

